Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility is currently unavailable.

Amir Tahmasb Fathi, M.D.

Co-Author

This page shows the publications co-authored by Amir Fathi and Philip Amrein.
Connection Strength

3.177
  1. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia. Cancer. 2020 03 15; 126(6):1264-1273.
    View in: PubMed
    Score: 0.227
  2. Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial. Lancet Haematol. 2020 Feb; 7(2):e122-e133.
    View in: PubMed
    Score: 0.227
  3. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. 2019 02 15; 125(4):541-549.
    View in: PubMed
    Score: 0.210
  4. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. Blood Adv. 2017 Oct 24; 1(23):2032-2040.
    View in: PubMed
    Score: 0.195
  5. Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. Cancer. 2018 01 15; 124(2):306-314.
    View in: PubMed
    Score: 0.195
  6. Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):988-991.
    View in: PubMed
    Score: 0.193
  7. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study. Cancer. 2017 Jul 01; 123(13):2561-2569.
    View in: PubMed
    Score: 0.189
  8. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. Haematologica. 2017 04; 102(4):719-727.
    View in: PubMed
    Score: 0.185
  9. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. Cancer. 2016 Aug 01; 122(15):2379-88.
    View in: PubMed
    Score: 0.177
  10. Presentation and outcomes among patients with isolated myeloid sarcoma: a Surveillance, Epidemiology, and End Results database analysis. Leuk Lymphoma. 2015 Jun; 56(6):1698-703.
    View in: PubMed
    Score: 0.158
  11. Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res. 2014 Jul; 38(7):773-80.
    View in: PubMed
    Score: 0.153
  12. Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemia. Am J Hematol. 2013 Aug; 88(8):642-6.
    View in: PubMed
    Score: 0.144
  13. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 2012 Nov 29; 120(23):4649-52.
    View in: PubMed
    Score: 0.138
  14. CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosis. Leuk Lymphoma. 2013 Apr; 54(4):860-3.
    View in: PubMed
    Score: 0.138
  15. Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy. Leukemia. 2020 11; 34(11):3050-3054.
    View in: PubMed
    Score: 0.059
  16. Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal Prophylaxis. Clin Lymphoma Myeloma Leuk. 2020 Nov; 20(11):e883-e889.
    View in: PubMed
    Score: 0.059
  17. Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangement. Blood Adv. 2020 01 14; 4(1):106-111.
    View in: PubMed
    Score: 0.057
  18. Outcomes for older adults with acute myeloid leukemia after an intensive care unit admission. Cancer. 2019 11 01; 125(21):3845-3852.
    View in: PubMed
    Score: 0.055
  19. Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes. Leuk Lymphoma. 2019 12; 60(12):3058-3062.
    View in: PubMed
    Score: 0.055
  20. Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia. 2019 10; 33(10):2393-2402.
    View in: PubMed
    Score: 0.054
  21. Patient-Clinician Discordance in Perceptions of Treatment Risks and Benefits in Older Patients with Acute Myeloid Leukemia. Oncologist. 2019 02; 24(2):247-254.
    View in: PubMed
    Score: 0.052
  22. A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia. Am J Hematol. 2018 02; 93(2):254-261.
    View in: PubMed
    Score: 0.049
  23. Asparaginase Erwinia chrysanthemi effectively depletes plasma glutamine in adult patients with relapsed/refractory acute myeloid leukemia. Cancer Chemother Pharmacol. 2018 01; 81(1):217-222.
    View in: PubMed
    Score: 0.049
  24. Potentially avoidable hospital admissions in older patients with acute myeloid leukaemia in the USA: a retrospective analysis. Lancet Haematol. 2016 Jun; 3(6):e276-83.
    View in: PubMed
    Score: 0.044
  25. Health care utilization and end-of-life care for older patients with acute myeloid leukemia. Cancer. 2015 Aug 15; 121(16):2840-8.
    View in: PubMed
    Score: 0.041
  26. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev. 2014 Mar 01; 28(5):479-90.
    View in: PubMed
    Score: 0.038
  27. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Leuk Res. 2013 Sep; 37(9):1016-20.
    View in: PubMed
    Score: 0.036
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.